Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News


Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
distributed by
React to this article
Latest news
Date Title
06:52a RESEARCH AND MARKETS : Global Visceral Pain Pipeline Review, H2 2015 - 12 Companies & 19 Drug Profiles
06:50a RESEARCH AND MARKETS : Assessment of China's Market for Stationary Air Compressors 2015-2016
06:49a ROTO SMEETS : Press release following the Extraordinary Gen. Meeting of Shareholders 27-11-2015
06:49a ADVA OPTICAL NETWORKING SE : Acquires Engineering Division from Technology Incubator
06:49a OPPORTUNITY INVEST MGMT : 27 november 2015 - Announcement AGM on 22 december 2015
06:49a OPPORTUNITY INVEST MGMT : 27 november 2015 - Annual report and financial statements for the year ended 31.12.2014
06:46a GREAT WESTERN MINING : Speech: We are making the Midlands an engine for growth
06:44a Bank of England fines Raphaels Bank 1.3 million pounds for outsourcing failure
06:44a TMT INVESTMENTS : Pipedrive partial exit and revaluation
06:44a SAVILLS : boosts property managment team with new appointment
Latest news
Hot News 
OPPORTUNITY INVEST MGMT : 27 november 2015 - Announcement AGM on 22 december 2015
ORCO PROPERTY : Group : Q3 2015 Financial Results
REALDOLMEN : HY 2015-2016 press release
IMAGINATION TECHNOLOGIES : Sir Hossein Yassaie receives 2015 Lifetime Achievement Award in annual Elektra European Electronics Industry Award...
LMS CAPITAL : Plans To Return Further GBP40.0 Million To Shareholders
Most Read News
11/26 PROTASCO BHD : Others
11/26 CREDIT CHINA : Acquires 35% Equity Interest in Genesis Business at a Consideration of RMB560 Million to Create “Chinese Version SQUARE”
11/26 DELEUM BHD : Dealings in listed securities (chapter 14 of listing requirements) : dealings outside closed period
11/26 Net Asset Value(s)
11/26 PEMEX PETRÓLEOS MEXICANOS : decreased the accident frequency rate by more than 33 percent
Most recommended articles
06:44a Bank of England fines Raphaels Bank 1.3 million pounds for outsourcing failure
06:37aDJMARKET SNAPSHOT : U.S. Futures Edge Up, As Investors Shrug Off China To Focus On Black Friday
06:35a DAX 30 Levels to Aim Beyond Next Week’s ECB Meeting
06:34a EU regulators say farmers can form cartels under certain conditions
06:31a Oddo launches 760 millionn euro offer for BHF Kleinwort Benson